Nyhet

PHI’s acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

Nyhet från Biostock

Publicerad: 01 Apr 09:12

With the introduction of the HoloMonitor CellSync, Phase Holographic Imaging (PHI) leaps forward in live cell imaging technology.

Currently in the final stages of development, this next-generation imaging system is undergoing pre-production testing at prestigious U. S.

institutions – the Huntsman Cancer Institute and the Wake Forest Institute of Regenerative Medicine.

Lorem ipsum dolor sit amet. Est omnis iusto eos velit nostrum et pariatur quod non. Consequuntur nemo id dolores tempora ut quis quis eum. Porro dolore rem voluptas iste. Consequuntur nemo id dolores tempora ut quis quis eum

•Denna källa har få eller inga artiklar bakom betalvägg

Läs hela artikeln hos Biostock

Börskollen

För dig med koll på börsen

Nyhet

PHI’s acting CEO: ”We aim to drive innovation that accelerates breakthroughs in regenerative medicine”

Nyhetsbrev